EU projects

Subsidies for innovations – we invest in your future

‘Establishment of the Centre for Research and Development of Biotechnology Products in IBSS BIOMED’, co-financed from public funds under sub-measure 4.5.2 Support for investments in the modern services sector and 4.5 Support for investments of high priority for the economy of the priority axis 4 Investments in innovative undertakings of the Innovative Economy Operational Programme, 2007 – 2013.

Name of the beneficiary: 
Instytut Biotechnologii Surowic i Szczepionek BIOMED Spółka Akcyjna

Project value: 
PLN 9,896,899.80

Participation of the European Union: 
PLN 4,023,130.00

Performance Period: 
2012 – 2015

Project description

The main objective of this project is to increase the innovation and competitiveness of the Company on the domestic and international market by creating in its structure a completely new organisational unit operating within the company, i.e. the Centre for Research and Development of Biotechnology Products (hereinafter referred to as the CBR), which will perform research and development operations in the field of biotechnology, related to the development of new and improved products, in two main research areas:

1. the development of new alternative products for antibiotics,
2. the development of new and the improvement of existing products for the prevention and control of bacterial infections, including antibiotics.

As such, research will focus on the development of new antibiotic-resistant products for the elimination of infections, including antibiotic-resistant, using a different mechanism of action than current antibiotics, and the improvement of existing products for the prevention and control of antibiotic-resistant bacterial infections.

In addition, CBR will carry out expert research for the Company’s needs in the field of literature analysis and patent analysis, as well as didactic activities for the needs of university students who annually complete student internships at IBSS BIOMED S.A.

The main objective of the project will be implemented through the achievement of specific objectives including:

• creating 11 new research posts;
• ensuring a high percentage of newly admitted employees with higher education – 100%;
• introducing 2 new innovative products manufactured according to the new technology to the offer:
  1. a preparation for dry and atopic skin care,
  2. a preparation intended for use in the inflammation of the throat;
• improved Pseudovac vaccine;
• development of a new product on the Q10 scale for use on wounds and ulcers infected with antibiotic-resistant bacteria;
• development and implementation of a new analytical method – an alternative method to animal testing in the evaluation of the activity of diphtheria-tetanus vaccines;
• introduction and implementation of new technology for the production of biotechnology products;
• development of cleaning technology and concentration of bacterial supernatants;
• establishing cooperation with at least 3 entities from the SME sector;
• implementation of new research projects in the field of biotechnology;
• development and validation of new analytical methods;
• introducing solutions contributing to ensuring equality between women and men and non-discrimination;
• introduction of solutions resulting in a positive impact on environmental protection.

In addition, the implementation of the project will have an impact on the socio-economic environment, i.e. including:

• creating new posts in the high technology industry;
• ensuring accessibility for Polish biotechnology specialists to state-of-the-art research technologies, and thus providing them with development opportunities;
• stimulating the development of Polish science in the area of biotechnology;
• introducing innovative products on the European market in response to a growing social problem, i.e. an increase in dangerous infections caused by antibiotic-resistant bacteria, and thus a significant positive impact on improvement in the field of health care policy;
• providing final recipients, i.e. patients with access to innovative and safe methods of prevention and treatment.

The scope of the investment:

1. Modernisation and adaptation of the premises owned by the Company (on the area of ​​
   49 m²), in order to create a Technological Laboratory and a modern double-corridor Animal House.
2. Establishment of research laboratories (extension of the building area: 562.20 m²) including: Immunology, Phage, Chemistry, Cell Culture, and Microbiology Laboratories, Laboratory for the Preparation of Reagents and Samples, Equipment Room, Reagent Storage and small laboratory equipment for auxiliary and social rooms.
3. Purchase of fixed assets including: a) research equipment for CBR laboratories; b) equipment of the Animal Farm; and c) furniture fittings for laboratories and social rooms of the CBR.

Recommended sites:

www.poig.gov.pl
www.mr.gov.pl
www.europa.eu

Subsidies for innovations – we invest in your future

‘The development of phage therapy in the treatment of antibiotic-resistant infections, with special emphasis on oncological patients’, co-financed from public funds under Measure 1.5. System projects of the National Centre for Research and Development, Operational Programme Innovative Economy, 2007 – 2013.

Name of the beneficiary: 
Instytut Biotechnologii Surowic i Szczepionek BIOMED Spółka Akcyjna

Project value: 
PLN 8,361,158.88

Subsidy: 
PLN 3,027,803.63

Performance Period:
2014 – 2019

Project carried out in the Scientific and Industrial Consortium: IBSS BIOMED S.A. – Jagiellonian University Collegium Medicum.

Consortium Leader: IBSS BIOMED S.A.

Project description

The main goal of the project is to search for and develop an innovative topical drug intended for the elimination of existing inflammation and infection with the etiology of Staphylococcus aureus and/or Pseudomonas aeruginosa. The active substance of the product developed under this project will be bacteriophages (i.e. bacterial viruses) directed against the foregoing pathogens. This product will allow the introduction of phage therapy as a standard form of treatment for routine clinical practice.

The solution proposed by the Beneficiary expands beyond the current state of knowledge, breaks the cognitive barriers of modern medicine and opens up new research areas. The project will carry out R&D works related to the selection of phages for therapy, development of a medicinal product, its testing on a laboratory scale and Q10 and non-clinical and clinical examinations.

The genesis of this project is closely related to the global problem of the rapidly growing antibiotic resistance of pathogens with the simultaneous absence of alternative therapies to antibiotics. A number of scientific publications that have appeared in recent years on bacteriophages and their potential use in therapy, IITD PAN experience and Russian and Georgian centres in the therapeutic use of phages makes the research topic undertaken by the Consortium create an actual opportunity to develop a new strategy for treatment of wounds infected with bacterial pathogens. Wound infections, ulcers and bedsores are an important clinical problem for many hospital units, especially those treating neoplastic diseases. Oncological patients are a group that is particularly at risk of infection, which are one of the most common complications during or after oncological treatment.

The addressed research topic is a response to the global problem of antibiotic-resistant infections – recognised as one of the main health threats in the 21^st century and as a priority topic in public health protection by a number of organisations and agencies around the world including the World Health Organization (WHO), the European Parliament, The European Centre for Disease Prevention and Control (ECDC), the American Center for Prevention and Control of Infections (CDC) and the US Food and Drug Administration (FDA), thereby responding to the identified market demand.

Recommended sites:
www.poig.gov.pl
www.mr.gov.pl
www.europa.eu